AUBURNDALE, Mass.--(BUSINESS WIRE)-- "…cappella has only scratched the surface in terms of the adaptability, application, and unique delivery system for its nitinol platform.” -- Martin B. Leon, M.D., Cappella’s Chief medical officer and Co-Founder of the TCT conference. Cappella Inc., developer of breakthrough solutions for coronary artery disease (CAD), participated in the Cardiovascular Research Foundations’ nineteenth annual “Transcatheter Cardiovascular Therapeutic” (TCT) 2007 scientific symposium that took place from October 21 through October 26 in Washington, D.C.
